Detail akcie ArriVent Bio Rg online

Business Summary: ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Company is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Arrivent Biopharma Inc revenues was not reported. Net loss increased from $59.9M to $130.8M. Higher net loss reflects Biopharmaceutical company segment loss increase of 96% to $138.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.96 to -$3.63.